Individual genotyping for HPV 16 & 18 enables clinicians to make more informed patient management decisions.
The cobas® HPV Test is the only clinically validated, FDA-approved assay that simultaneously provides individual results on the highest-risk genotypes – HPV 16 and HPV 18 – and a pooled result on the twelve other high-risk HPV (hrHPV) genotypes, all in one run from one patient sample.
HPV 16 and 18 are the two most prevalent oncogenic HPV types in both squamous cell carcinoma and adenocarcinoma and are responsible for more than two-thirds of all cervical cancer cases.1,2
The cobas® HPV Test delivers 3 high-risk HPV results in one test, enabling clinicians to risk stratify patients and help guide patient management decisions.
By choosing the right HPV test, labs can provide the accurate hrHPV information that clinical partners expect and patients deserve. Learn how the cobas® HPV Test design impacts patient management.
"Getting 3 results in 1 HPV test has changed the way I treat patients with atypical Pap results.”
The cobas® HPV Test simplifies lab logistics by minimizing the laboratory burden of juggling multiple vendor platforms for HPV testing. The cobas® HPV Test’s 3 results in 1 test provides physicians with more clinically relevant information up-front so that their patients can receive better, less costly care.
In 2013, the Medicare National Correct Coding Initiative changed the number of allowable units under Current Procedural Terminology (CPT®)3 code 87621 (HPV amplified probe) from 3 units to 1 unit, meaning that CPT code 87621 can only be reported once per claim line. With the cobas® HPV Test laboratories do not have to worry about confirming coverage for reflex genotyping because the test provides 3 results with one run – HPV 16, HPV 18, and a high-risk pool of 12 other hrHPV genotypes.
Find out more about this coding edit change and how it affects reimbursement.
1. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072-1079.
2. Bosch FX, de Sanjosé S. Human papillomavirus and cervical cancer — burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;31:3-13.
3. CPT is a registered trademark of the American Medical Association Copyright 2011, American Medical Association. All rights reserved.